基于西妥昔单抗的化疗是治疗复发性和/或转移性头颈部鳞状细胞癌 (R/M SCCHN) 的标准一线治疗方法。然而，很少有研究报道由 PCE 方案（紫杉醇卡铂西妥昔单抗）随后免疫检查点抑制剂组成的治疗序列的生存数据。我们回顾性评估了 37 例口腔、口咽、下咽和喉部的 R/M SCCHN 患者2016 年 12 月至 2021 年 7 月期间，在国家癌症中心东医院接受 PCE 作为一线治疗，随后接受纳武单抗作为二线治疗的患者。为了进行比较，我们还分析了 14 名在 PCE 后未接受纳武单抗治疗的患者。在 37 名接受纳武单抗治疗的患者中，接受纳武单抗治疗后，PCE 的总体缓解率 (ORR) 为 48.6%，中位缓解时间和中位无进展生存期 (PFS) 分别为 2.1 个月（范围：0.8-4.8）和 4.4 个月。在纳武单抗阶段，ORR 为 10.8%。 23名患者接受了三线治疗。中位 PFS2、PFS3 和总生存期 (OS) 分别为 6.8、11.6 和 19.5 个月。 PD-L1 表达的亚组分析显示 OS 没有显着差异。对对照组的分析显示，与未接受纳武单抗治疗的患者相比，接受纳武单抗治疗的患者 OS 有改善的趋势（HR 0.47，95% CI [0.19-1.13]，p = 0.084）。随后进行纳武单抗治疗的 PCE 显示出良好的生存结果，代表了 PCE 快速肿瘤反应的潜力，以及通过添加纳武单抗延长 OS 的潜力，无论综合阳性评分如何。版权所有 © 2023 Elsevier Ltd。保留所有权利。

Cetuximab-based chemotherapy is a standard 1st-line treatment for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). However, few studies have reported survival data for a treatment sequence consisting of a PCE regimen (paclitaxel + carboplatin + cetuximab) followed by an immune checkpoint inhibitor.We retrospectively assessed 37 patients with R/M SCCHN from the oral cavity, oropharynx, hypopharynx, and larynx who received PCE as 1st-line treatment followed by nivolumab as 2nd-line at the National Cancer Center Hospital East between December 2016 and July 2021. For comparison, we also analyzed 14 patients who did not receive nivolumab after PCE.Of the 37 patients who received nivolumab, overall response rate (ORR) by PCE was 48.6%, and median time to response and median progression-free survival (PFS) were 2.1 months (range: 0.8-4.8) and 4.4 months, respectively. In the nivolumab phase, ORR was 10.8%. 23 patients received 3rd-line therapy. Median PFS2, PFS3, and overall survival (OS) were 6.8, 11.6, and 19.5 months, respectively. Subgroup analysis by PD-L1 expression showed no significant difference in OS. Analysis of the comparison group revealed a trend toward improved OS in those who received nivolumab compared to those who did not (HR 0.47, 95%CI [0.19-1.13], p = 0.084).PCE followed by nivolumab shows a favorable survival outcome, representing the potential for rapid tumor response with PCE and extension of OS by the addition of nivolumab regardless of combined positive score.Copyright © 2023 Elsevier Ltd. All rights reserved.